ReAlta Life Sciences

Executive Summary

ReAlta Life Sciences is a clinical-stage biotechnology company focused on developing complement-targeted therapeutics for inflammatory and rare diseases. The company's lead program, pegtarazimod (RLS-0071), is a first-in-class dual inhibitor of complement and neutrophil-driven inflammation, initially targeting neonatal hypoxic-ischemic encephalopathy (HIE), a devastating condition with no approved therapies. Building on discoveries in astrovirus evolutionary biology, ReAlta's platform enables the engineering of peptides that modulate immune responses with high specificity. The company has demonstrated preclinical efficacy in HIE models and is advancing clinical development while exploring additional indications such as inflammatory bowel disease and transplantation. As a private entity, ReAlta has not disclosed funding details but continues to attract interest from investors seeking novel immunomodulatory approaches. ReAlta's strategy focuses on rapidly advancing pegtarazimod through clinical trials to address significant unmet needs in rare pediatric populations. The company recently completed a Phase 1 study and is preparing for Phase 2 trials in HIE, with potential for expedited regulatory pathways given the severity of the disease. With a strong intellectual property portfolio and a differentiated mechanism of action, ReAlta represents a promising opportunity in the complement therapeutics space. Key upcoming milestones include initial efficacy data from ongoing studies and potential partnering discussions as the program matures.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 trial for pegtarazimod in neonatal HIE70% success
• Q3 2026Presentation of Phase 1 safety and biomarker data at a medical conference85% success
• Q2 2026FDA Rare Pediatric Disease Designation for pegtarazimod in HIE80% success